---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-190074"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2023-07-20T23:59:59+00:00"
generated_at: "2026-06-13T05:42:05.479906+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eliem halts Kv7 program, explores strategic alternatives including sale or merger

## Summary
- Halts further development of Kv7 program; shifts focus to maximizing shareholder value.
- Engages Leerink Partners as strategic advisor to explore acquisition, merger, or business combination.
- Reports preliminary unaudited cash, cash equivalents, and marketable securities of ~$102.6M as of June 30, 2023.
- No timetable set for strategic review; no assurance any transaction will occur.

## SEC filing metadata
- accession: 0001193125-23-190074
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2023-07-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312523190074/0001193125-23-190074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312523190074/d485991d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-190074
- JSON: https://secwatch.observer/filing/0001193125-23-190074.json
- Plain text: https://secwatch.observer/filing/0001193125-23-190074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.